Results 171 to 180 of about 1,044,728 (382)
Supplementary Fig.S1 from Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E–based Antibody–Drug Conjugate for Treatment of Nectin-4–expressing Cancers
, 2023 Wei Zhou, Peng Fang, Dongan Yu, Hongyuan Ren, Meng You, Long Yin, Fei Mei, Huikai Zhu, Zhenzhen Wang, Hui Xu, Yuxia Cao, Xiaowei Sun, Xiaohong Xu, Jianjun Bi, Jin Wang, Lanping Ma, Xin Wang, Lin Chen, Yongliang Zhang, Xiaowei Cen, Xi Zhu, Liguang Lou, Datao Liu, Xiaoding Tan, Jinliang Yang, Tao Meng, Jingkang Shen +26 moreopenalex +2 more sourcesEstablishment of Human Bone Marrow-on-Chip As a Preclinical Model to Evaluate Drug-Induced Toxicities and Myelofibrosis Patient-Specific Pathophysiology
, 2023 Manti Guha, Ronald Dove, Aragaw Gebeyehu, Daniel Merenich, Paul Collier, Erin L. Crowgey, Mike Schaffer, Dana Shuey, Ricardo Macarrón, Alejandro Amador Arjona +9 moreopenalex +1 more sourceLong‐Term Evaluation of Givinostat in Duchenne Muscular Dystrophy, and Natural History Comparisons
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objectives
This ongoing, open‐label extension study is evaluating the long‐term safety, tolerability, and efficacy of givinostat, a Class I and II histone deacetylase inhibitor, in patients with Duchenne muscular dystrophy (DMD). Methods
The recruited patients completed one of two prior clinical studies (one Phase 2 and one Phase 3 [EPIDYS ...Craig M. McDonald, Michela Guglieri, Dragana Vučinić, Gyula Acsadi, John F. Brandsema, Claudio Bruno, Erika L. Finanger, Amy Harper, Mercedes Lopez Lobato, Riccardo Masson, Nuria Muelas, Francina Munell, Yoram Nevo, Yann Péréon, Han Phan, Valeria A. Sansone, Mariacristina Scoto, Tracey Willis, Richard S. Finkel, Krista Vandenborne, Sara Cazzaniga, Silvia Montrasio, Federica Alessi, Paolo Bettica, Eugenio Mercuri, for the Givinostat Study 51 Investigators, the Cooperative International Neuromuscular Research Group (CINRG) Duchenne Natural History Study (DNHS) Investigators, the ImagingDMD Investigators, Enrico Bertini, Giacomo Pietro Comi, Eugenio Maria Mercuri, Giuseppe Vita, Sonia Messina, Claudio Bruno, Riccardo Masson, Valeria Sansone, Nathalie Goemans, Liesbeth De Waele, Laurent Servais, Teresa Gidaro, Odile Boespflug‐Tanguy, Yann Péréon, Jessika Johannsen, Astrid Blaschek, Ulrike Schara‐Schmidt, Erik Niks, Imelda de Groot, Saskia Houwen‐van Opstal, Andres Nascimento, Juan Jesus Vilchez, Nuria Muelas, Francina Munell, Marcos Madruga Garrido, Mercedes Lopez Lobato, Michaela Guglieri, Tracey Willis, Stefan Spinty, Daniel Hawcutt, Mariacristina Scoto, Jean K. Mah, Laura McAdam, Kathryn Selby, Katherine Mathews, Craig McDonald, Craig Zaidman, Barry Byrne, John Brandsema, Gyula Acsadi, Chamindra Laverty, Amy Harper, Erika Finanger, Han Phan, Yoram Nevo, Vedrana Milic Rasic, Dragana Vucinic +74 morewiley +1 more sourceSYHA1813, A VEGFR and CSF1R Inhibitor, in Patients With Recurrent High‐Grade Gliomas: A Multicenter, Open‐Label Phase I Study
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective
Recurrent high‐grade gliomas have a poor prognosis and limited therapeutic options. This study aimed to evaluate the safety and efficacy of SYHA1813, a dual inhibitor of VEGFR and CSF1R, in patients with recurrent high‐grade gliomas.Zhuang Kang, Shenglan Li, Liang Wang, Qianxue Chen, Weiguo Hu, Ting Lei, Ying Mao, Jing Zhang, Xiaojun Xiang, Qiming Wang, Zhengwen He, Tao Sun, Yulei Wang, Mengqian Huang, Rong Zhang, Feng Chen, Wenbin Li +16 morewiley +1 more sourceQuantitative 3D histochemistry reveals region-specific amyloid-β reduction by the antidiabetic drug netoglitazone.
PLoS ONEA hallmark of Alzheimer's disease (AD) is the extracellular aggregation of toxic amyloid-beta (Aβ) peptides in form of plaques. Here, we identify netoglitazone, an antidiabetic compound previously tested in humans, as an Aβ aggregation antagonist ...Francesca Catto, Daniel Kirschenbaum, Athena E Economides, Anna Maria Reuss, Chiara Trevisan, Davide Caredio, Ehsan Dadgar-Kiani, Delic Mirzet, Lukas Frick, Ulrike Weber-Stadlbauer, Sergey Litvinov, Petros Koumoutsakos, Jin Hyung Lee, Adriano Aguzzi +13 moredoaj +1 more sourceNR4A1 Exerts Pro‐Tumor Role in Glioblastoma via Inducing xCT/GPX4‐Regulated Ferroptosis
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Purpose
This study investigates NR4A1's paradoxical roles in glioblastoma (GBM) progression, focusing on its mechanistic link to ferroptosis regulation. We aimed to resolve conflicting reports of NR4A1 as both an oncogene and a tumor suppressor by defining its transcriptional control over xCT/GPX4‐mediated iron homeostasis and its clinical ...Peng Tao, Shikuan Din, Zhengkang Fu, Qian Sun, Xiwei Zhu, Yuxin Wei, Huan Qu, Xinyi Zhang, Jiaxuan Liu, Chuhua Fu, Qianxue Chen +10 morewiley +1 more sourceGenetic Modifiers of Parkinson's Disease: A Case–Control Study
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective
To examine the associations of LRRK2 p.G2019S, GBA1 p.N409S, polygenic risk scores (PRS), and APOE E4 on PD penetrance, risk, and symptoms. Methods
We conducted a US‐based observational case–control study using data from the 23andMe Inc. and Fox Insight Genetic Substudy (FIGS) databases.Matthew J. Kmiecik, Michael V. Holmes, Pierre Fontanillas, Giulietta M. Riboldi, Ruth B. Schneider, Jingchunzi Shi, Anna Guan, Susana Tat, Steven Micheletti, Keaton Stagaman, Josh Gottesman, David A. Hinds, Joyce Y. Tung, 23andMe Research Team, Stella Aslibekyan, Lucy Norcliffe‐Kaufmann +15 morewiley +1 more sourceSupplementary Table S12 from Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E–based Antibody–Drug Conjugate for Treatment of Nectin-4–expressing Cancers
, 2023 Wei Zhou, Peng Fang, Dongan Yu, Hongyuan Ren, Meng You, Long Yin, Fei Mei, Huikai Zhu, Zhenzhen Wang, Hui Xu, Yuxia Cao, Xiaowei Sun, Xiaohong Xu, Jianjun Bi, Jin Wang, Lanping Ma, Xin Wang, Lin Chen, Yongliang Zhang, Xiaowei Cen, Xi Zhu, Liguang Lou, Datao Liu, Xiaoding Tan, Jinliang Yang, Tao Meng, Jingkang Shen +26 moreopenalex +1 more source
